JC03 Rec'd PCT/PTO 2 6 SEP 2005

-FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 2-2005) ATTORNEY'S DOCKET NUMBER KPO-LTT-P1/LTT-85/US TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) to be ass CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE March 26, 2003 PCT/JP2004/003246 March 11, 2004 TITLE OF INVENTION INTRAVENOUS NANOPARTICLES FOR TARGETING DRUG DELIVERY AND SUSTAINED DRUG RELEASE APPLICANT(S) FOR DO/EO/US ISHIHARA, Tsutomu MIZUSHIMA, Yutaka Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. \boxtimes This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), \boxtimes 3. (9) and (24) indicated below. \boxtimes The US has been elected (Article 31). 4. 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). a. 🛛 b 🖾 has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). c. 🗆 An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). \Box 6. а. 🗆 is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). b. 🗆 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) 7. are attached hereto (required only if not communicated by the International Bureau). a. 🗆 have been communicated by the International Bureau. c. 🗀 have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 9. An English language translation of the annexes to the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)). 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409). A copy of the International Search Report (PCT/ISA/210). 12. Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. 15. A FIRST preliminary amendment. 16 A SECOND or SUBSEQUENT preliminary amendment. 17 A substitute specification. with Doctarotion . \boxtimes A power of attorney and/or change of address letter. 18. 19 A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 20 A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 21. \boxtimes EV501833962US 22 Express Mail Label No. 23. Other items or information:

Certified Translation of Priority Application JP2003-084695; PCT/IB/301; PCT/IB/304; PCT/IB/311 with International Publication

No. WO 2004/084871 A1; PCT/ISA/220 enclosing PCT/ISA/210 and PCT/IPEA/237

JCO9 Rec'd PCT/PTO 26 SEP 2005

PTO-1390 (Rev. 02-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known see 37 CEP 15)

INTERNATIONAL APPLICATION NO (if known see 37 CEP 15)

U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER						
tool signed U 9 9 PCT/JP2004/003246					KPO-LTT-P1/LTT-85/US			
The following fees are submitted: 24. Basic national fee							CALCULATIONS	PTO USE
			• • • • • • • • • • • • • • • • • • • •			\$300	\$ \$300.00	
25. Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4). \$100 All other situations. \$200						\$ \$200.00		
26. Search fee						\$ \$400.00		
TOTAL	L OF 24, 25 and	26 =	61-4:	00 - 1-		(avalualia a	\$ \$900.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra Sheets	Number o	f each additional 50 eof (round up to a w	or		RATE		
- 100 =	0 /50 =		0		×	\$250.00	\$ \$0.00	
	0.00 for furnishing oriority date (37 Cl		eclaration later than	month	s fro	m the	\$	
CLAIMS	NUMBER F	ILED N	UMBER EXTRA		RA	TE		
Total claims	18	- 20 =	0	х		\$50.00	\$ \$0.00	
Independent clair	ns 2	3 =	0	×		\$200.00	\$ \$0.00	
MULTIPLE DEPE	NDENT CLAIMS	(if applicable)		+		\$360.00	\$ \$0.00	
TOTAL OF ABOVE CALCULATIONS =						\$ \$900.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ \$0.00				
SUBTOTAL =				\$ \$900.00				
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					\$ \$0.00			
TOTAL NATIONAL FEE =					\$ \$900.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +					\$ \$0.00			
TOTAL FEES ENCLOSED =					\$ \$900.00			
							Amount to be	\$
							Amount to be	\$
a. 🛛 A check	in the amount of \$	\$900.00	to cover the	above	fees	is enclosed.		
b. Please charge my Deposit Account No in the amount of to cover the above fees.						r the above fees.		
A duplicate copy of this sheet is enclosed. c. 🗵 The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment						ayment		
	sit Account No to be charged to	50-3195 a credit card.	A duplicate co WARNING: Informa	-			osed. ecome public. Credit c a	ard
informa	tion should not b	e included o	n this form. Provide	credit	card	d information	and authorization on P	TO-2038.
			37 CFR 1.495 has ational Application				on to revive (37 CFR 1	.137(a) or (b))
SEND ALL CORRESPONDENCE TO:					M	achte		
Customer No. 44702 SIGNATURI Manette Dennis								
Ostrager Chong Flaherty & Broitman PC					ennis			
250 Park Avenue Suite 825 New York, New York 10177-0899 30.623								
212 681 0600 mdennis@octblaw.com					REGISTRAT	TON NUMBER		
							- · · · · · - · · · · · · · · · · · · ·	

10/550990

CERTIFICATE OF Applicant(s): Ishihara		PRESS MAIL" (37 C 1409 1 Rec		26 N SEP 23 P1/LTT-85/US
Application No. to be assigned	Filing Date Sept. 26, 2005	Examiner to be assigned	Customer No. 44702	Group Art Unit
nvention: INTRAVE RELEASE	NOUS NANOPARTICLE	S FOR TARGETING DRUG DELIVE	ERY AND SUSTA	INED DRUG
I hereby certify that t	he following corresponde	ence:		
Transmittal Letter 35 U.S.C. 371	to the United States Desig	nated/Elected Office (DO/EO/US) Cor	cerning a Submis	sion under
	(1	dentify type of correspondence)		
		stal Service "Express Mail Post Office missioner for Patents, P.O. Box 1450		
	•	Manette	Dennis	
		(Typed or Printed Name of Pers	on Mailing Correspond	tence)
			& D	
		(Signature of Person Ma	iling Correspondence)	
		EV50183	3962US	
		("Express Mail" Mail	ing Label Number)	
		per must have its own certificate of mailing		

10/550990

			101	770 770
CERTIFICATE O	F MAILING BY "EX	PRESS/MAIL" (37 CFR 1.10)	C'd PCT/PHQ	ke GNE. SEP Z
pplicant(s): Ishihara	i, T. et al,		KPO-LTT-	P1/LTT-85/US
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit
to be assigned	Sept. 26, 2005	to be assigned	44702	ТВА
intrave RELEASE		S FOR TARGETING DRUG DELIVE	RY AND SUSTA	INED DRUG
I hereby certify that	the following corresponde	ence:		
Certified Translation	on of Priority Application	JP2003-084695, filed March 26, 2003		
L	(I	dentify type of correspondence)		J
is being deposited w	ith the United States Pos	stal Service "Express Mail Post Office	to Addressee" s	ervice under 37
CFR 1.10 in an enve	elope addressed to: Com	missioner for Patents, P.O. Box 1450	, Alexandria, VA	22313-1450 on
	September 26, 2005			
	(Date)			
		Manette (Typed or Printed Name of Perso		J
		(Typea or Printea Name of Perso	n Mading Correspond	ience)
		(Signature of Person Mai	Men.	-
EV501833962US ("Express Mail" Mailing Label Number)				
		(Express mun muni	ng Luoci i mimoci)	
				÷
	Note: Fach par	per must have its own certificate of mailing		
	Note: Each pap	or must have its own certificate or maining	•	